A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study Academic Article uri icon

Overview

MeSH Major

  • Boronic Acids
  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms
  • Peritoneal Neoplasms
  • Pyrazines

abstract

  • Bortezomib has minimal activity as a single-agent in the treatment of recurrent platinum-sensitive EOC/PPC. Treatment with bortezomib at 1.5 mg/m(2)/dose was not feasible in this patient population due to excess toxicity. Bortezomib was well tolerated at 1.3 mg/m(2)/dose.

publication date

  • November 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ygyno.2009.07.023

PubMed ID

  • 19712963

Additional Document Info

start page

  • 215

end page

  • 20

volume

  • 115

number

  • 2